Compare IPWR & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPWR | PLUR |
|---|---|---|
| Founded | 2007 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 33.9M |
| IPO Year | 2013 | 2001 |
| Metric | IPWR | PLUR |
|---|---|---|
| Price | $3.35 | $3.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $10.75 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 84.2K | 6.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,336,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | $3,233.33 | $293.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 309.82 |
| 52 Week Low | $2.62 | $2.82 |
| 52 Week High | $6.90 | $7.13 |
| Indicator | IPWR | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 46.04 | 44.88 |
| Support Level | $2.91 | $3.13 |
| Resistance Level | $4.35 | $3.42 |
| Average True Range (ATR) | 0.37 | 0.17 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 43.73 | 18.95 |
Ideal Power Inc is pioneering the development of its broadly patented bidirectional power switches, creating efficient and ecofriendly energy control solutions for electric vehicles, electric vehicle charging, renewable energy, energy storage, UPS / data center, solid-state circuit breaker and other industrial and military applications. The company is focused on its patented Bidirectional, Bipolar Junction Transistor (B-TRAN) semiconductor technology. B-TRAN is a double-sided bidirectional AC switchable to deliver substantial performance improvements over conventional power semiconductors. The primary raw material used in the fabrication of B-TRAN devices is silicon wafers.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.